A non-invasive diagnostic tool that could identify malignancy in situ and in real time would have a major impact on the detection and treatment of cancer. We have developed and are testing early prototypes of an optical biopsy system (OBS) for detection of cancer and other tissue pathologies. The OBS invokes a unique approach to optical diagnosis of tissue pathologies based on the elastic scattering properties, over a wide range of wavelengths, of the microscopic structure of the tissue. The use of elastic scattering as the key to optical tissue diagnostics in the OBS is based on the fact that many tissue pathologies, including a majority of cancer forms, manifest significant architectural changes at the cellular and sub-cellular level. Since the cellular components that cause elastic scattering have dimensions typically on the order of visible to near-JR wavelengths, the elastic (Mie) scattering properties will be strongly wavelength dependent. Thus, morphology and size changes can be expected to cause significant changes in an optical signature that is derived from the wavelength-dependence of elastic scattering. The data acquisition and storage/display time with the OBS instrument is 1 second. Thus, in addition to the reduced invasiveness of this technique compared with current state-of-the-art methods (surgical biopsy and pathology analysis), the OBS offers the possibility of impressively faster diagnostic assessment.
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The OBS employs a small fiber-optic probe that is amenable to use with any endoscope, catheter or hypodermic, or to direct surface examination (e.g., as in skin cancer or cervical cancer). It has been tested in vitro on animal and human tissue samples, and clinical testing in vivo is currently in progress.
BACKGROUND AND SIGNIFICANCE
Early diagnosis appears to be an essential requirement for successful treatment of cancer, and tissue/cell analysis is the sine-qua-non key to diagnosis in oncology. The analyses are always accomplished in vitro: a biopsy is performed (or a sputum sample or swab is collected) and the tissue (or a cell group from a swab) is microscopically assessed by a pathologist. The results are then related to an in vivo condition. The physician is limited in the number of sites he/she can biopsy, and in many cases is only likely to choose sites where visible gross changes exist. If the macroscopic manifestations of cancer (hyperplasia, vascular proliferation, etc.) are not yet obvious to the naked eye, the physician is more likely to detect early malignancy with a system that can make rapid measurements on a larger number of sites.
Internationally, there is a strong emphasis on early cancer detection and on the reduction in the cost of providing medical care. Both of these issues would be directly addressed by the OBS technology.
There are obvious clinical benefits in an ability to determine malignancy of various tissues in situ and instantly. For example, during routine colonoscopy (especially in the presence of ulcerative colitis) it is envisioned that the physician could simply touch the tip of the optical fiber probe to any suspect tissue and the OBS would immediately display the signature, allowing the physician to recognize early malignant conditions "on the spot". In this manner more sites could be assessed than would be possible with conventional biopsy techniques. It should be noted, however, that the noninvasive benefit of the OBS technique is limited to detecting malignancy that is at, or near, an organ surface that can be reached by fiber. (The use of a syringe needle would be required to reach a suspected interstitial site such as liver or prostate.) When compared with some of the other optical techniques under development, the proposed OBS technique would have the additional advantage of not requiring the administration of drugs such as hematoporphyrin derivatives (HPD's) or other targeting fluorescers with their potential concomitant side effects.
OTHER APPROACHES TO OFFICAL BIOPSY
Other attempts at in situ real-time optical diagnostics have generally invoked singlecolor UV illumination and recording of the autofluorescence signal from the tissue.1 Laser-induced fluorescence spectroscopy (LIF) has limitations of when applied to complex and heterogeneous biological media since patient-to-patient variations can mask the differences between similar tissues (or subtle changes in a given tissue). Thus, LIF has shown limited reliability in detecting malignancy2 except with the (invasive) application of exogenous fluorescent dyes or drugs such as HPD used as targeting fluorescers3 ,4 ,5 or under highly-controlled conditions with sophisticated multicolor detection.6 The limitation is due primarily to broadly-absorbing chromophores with broadband and relatively featureless fluorescence emissions that overlap, compounded by variations in patient conditions (blood pH, hemoglobin saturation, etc.), which can add to the confusing variety in the "normal" condition.
A partial solution to the problem is to collect fluorescence spectra for a sequence of illumination wavelengths, from the UV through the visible. The different excitation wavelengths might be expected to variously excite different chromophores, resulting in more complex emission patterns with more information. Recently this approach, sometimes called "fluorescence contour mapping", has been used to generate more informative fluorescence spectroscopy signatures.7 The technique is based on earlier developments in the field of chemical engineering. 8 In this method fluorescence spectra are taken for a sequence of different excitation wavelengths. The data are then presented in a two-dimensional contour plot, graphing the fluorescence wavelength against the excitation wavelength for a given intensity. This matrix can be viewed as a topographic spectroscopic map whose topography comprises a group of "hills". The displayed shapes constitute an enhanced (more detailed) autofluorescence signature of the tissue, resulting from biochemical changes, with greater likelihood of distinguishing malignancy from normal conditions.10
OUR APPROACH
But what does a pathologist normally look for? After preparing a slide, a pathologist performs a microscopic assessment (histopathology) of the cell architecture or morphology: the sizes and shapes of cells, the ratio of nuclear to cellular volume, the form of the bilipid membrane, clustering patterns, etc. These changes will have an effect on the elastic scattering properties, separate from any inelastic scattering due to fluorescence. Thus, a more direct optical solution to the problem is to generate a signature that comprises data from the elastic scattering and absorption -the optical transport properties of the tissue. In cases where useful fluorescence information is also available, an instrument with the most general capabilities would also collect that data.
We have constructed and demonstrated an optical biopsy system (OBS) that is fiber-optic mediate; it collects and displays data in approximately 1-3 seconds (depending on what range of data is collected). The OBS invokes a special fiber-bundle design that allows the system to collect data on the elastic scattering and absorption properties of the tissue, in addition to the multiple-excitation-color fluorescence data if desired. Our laboratory and clinical tests indicate that these data result in a more reliable diagnostic signature than is possible with fluorescence data alone, in the organ areas tested. We have designed the OBS fiber probe to be used in optical contact with the tissue expressly to facilitate the collection of the tissue multiply-scattered signal. The fiber bundle is less than 1 mm in diameter, being easily reduced further in size, and can be passed readily through the working channel of most endoscopes.
Currently we are developing a simpler system that is limited to collecting only the elastic-scatter/optical transport signal. This system is inexpensive, smaller and faster.
Although we sacrifice the fluorescence data with this system, preliminary measurements have indicated that in many applications the "backscatter" signal alone is reliable for cancer detection, and in some cases it may provide the only useful signature.
It should be noted that the OBS does not image a tissue surface: rather, it provides a large amount of information about the optical transport and fluorescence properties of the tissue, for one spot at a time (where the fiber probe contacts the tissue).
SYSTEM DESCRIPTION
Light incident on tissue may be reflected from the surface, scattered or absorbed.
Because our probe is designed to be placed in direct contact with the tissue surface, as illustrated in Figure 1 , we avoid collecting light from simple surface reflection. Both the illuminating light delivered by the fiber(s) from the light source, and any fluorescence generated in the tissue, must scatter through the tissue (thus experiencing the elastic scattering and absorption properties of the tissue) before reaching the separate collection fiber(s) that lead to the spectrometer.
to Spectrometer Figure 1 . Light that enters the tissue from the illuminating fibers is modified by both elastic (optical transport) and inelastic scattering processes before being collected by the fibers that lead to the spectrometer.
The major elements of the Optical Biopsy System:
. The most general manifestation of the OBS employs a rapidly-tunable light source.
Light from a pulsed xenon point-arc lamp is collimated and focused on the entrance slit of a rapidly-tunable mini-monochromator. The source is capable of generating light pulses at 30 different wavelengths per second over the range <280nm to >1000 nm. (In typical use the range utilized is -280-850 nm, with sequential pulses every 10 mn.)
• The tuned light source is imaged onto one end of the "illumination' fibers that then join with the "collection" fibers to form the small (-0.8 mm diameter) fiber bundle of the optical probe.
• The collection fibers transmit the "backscattered" signal from the tissue back to the entrance slit of a small spectrometer. The spectrally dispersed signal at the exit plane is read by a multiple-element detector, such as an intensified diode array or CCD detector.
• The detector is interfaced, through a buffer/controller, to a PC.
• System software controls the illumination source and the data acquisition process, and then displays the signature on the computer's CRT. The signature can be presented in various ways, including false-color and quasi-3D displays. 
PRELIMINARY RESULTS
Testing of the first prototype OBS was carried out in vitro on tissue samples, both normal and malignant, from various canine organs (liver, lung, spleen, kidney and pancreas) and from human prostate.
The animal samples were preserved in formalin. In all organ types distinctive signature differentiation between malignant and normal tissue was generated by the OBS. Moreover, the differentiation between malignant and healthy tissue was clearly much greater than any variation among signatures from healthy sites for the same organ type. All results were corroborated by traditional pathology analyses. Figures 3 and 4 show the clearly distinguishable signatures of canine normal and malignant samples, in this case for the liver. These plot the spectrally-dispersed collected light for each illuminating wavelength in a pseudo-three-dimensional display. Other canine organ tissues exhibited similarly large changes between normal and malignant conditions, although, as expected, the general character of the signatures varied among the organ types. Since these malignancies were tumors that were obvious to the naked eye, it is not surprising that signature changes are manifested in both the elastic The first tests on human tissue samples were made on freshly-excised human prostate tissue that was not yet fixed. (It was placed in saline.) In one set of measurements the prostate, cross sectioned by the pathologist, showed no sign of malignancy that was visible to the unaided eye. However, the OBS data clearly distinguished one site from among several sites chosen randomly. That site was later found by pathology, under microscopic examination, to have contained early malignant changes. This distinction found by the OBS is illustrated in Figure 5 , which displays only the elastic opticaltransport component from the OBS data.
Clinical testing on superficial ocular lesions: We began our first in vivo human clinical tests in November 1992 at the University of Texas Health Science Center in San Antonio, in a clinical study of superficial lesions of the eye. The basic question that the study is designed to answer is whether the OBS signatures can be used to distinguish benign from malignant lesions. Initial comparisons with histopathology are very encouraging, and additional testing is generating a larger patient sample and good statistical correlations between the optical and physical biopsies. The OBS signatures are reliably different for lesions and normal tissue, with obvious differences among the backscattering spectra for various types of lesions and the normal tissues, whether the underlying tissue was conjunctiva/sclera or cornea/iris. (There was no useful fluorescence signal in any of these ocular measurements.) Most of the lesions were pigmented to some degree, and it was quickly apparent that the OBS signature could be used to locate the margins of the lesion with an 180 /SPIE Vol. 2081 Optical Biopsy (1993) prostate tissue with early maligr 400 accuracy limited only by the size of the handpiece tip. Interestingly, however, the OBSdetermined margins were often well outside the borders of visible pigmentation. This has correlated with histopathology reports, which show where that malignant changes in the cellular architecture were found outside the pigmented area. Figure 6 shows one example of the differentiations that were seen. with that A comparison of the OBS spectral signature of a pinguicula lesion from normal conjunctiva/sclera.
An interesting check can be made on the variability, from patient to patient and also for different physicians performing the measurement, of the OBS signatures for normal tissue. A total of 27 measurements were made on a number of normal sites in three patients by three different physicians. As can be seen in Figure 7 , the reproducibility of the spectral signature for normal sites is remarkable. Figure 7 . Normal sclera/conjunctiva reproducibility test: a set of 27 measurements performed by three different physicians on three different patients, all on presumptive normal sites. site. The backscatter signatures from the normal bladder wall and tumor sites were reproducible and contained significant differences. With 10O measured sites in 10 patients pathology diagnosis has been completely consistent. We also saw differences at sites of (presumptive) premalignant changes, but we are awaiting confirmation by histopathology. Fig. 8 shows an example of these data. This study is also continuing. an example of a set of OBS signatures for various '7. CURRENT ONGOING DEVELOPMENTS 1) A simplified version of the OBS that is limited to detecting only a spectrally dispersed backscatter signal (but not fluorescence) is being developed. This version differs in that the light from the xenon point-arc lamp is focused directly onto the delivery flb3r(s). The light from the collection fiber(s) is spectrally dispersed onto a low-cost linear CCD array which is interfaced to a PC. Such single spectra can be collected in milliseconds.
2) Development is planned of special probes and software to detect the depth of a lesion.
3) Measurements on bladder cancer at Lovelace Medical Center are continuing.
182 /SPIE Vol. 2081 Optical Biopsy (1993 200 300 400 500 600 700 4) As data are gathered from both in vitro and in vivo evaluations, the accumulated experience will be used to further improve and iterate the system design, especially the software.
5) We will begin to establish a data library of signatures for the various organ tissues studied. The purpose is to allow for a determination of the sensitivity and reliability of the tissue signatures generated. At this time we are developing the OBS with the intent that actual diagnosis should be made by the physician, or consulting pathologist, upon examination of the displayed signatures. However, for certain applications it is expected that system software itself would be capable of establishing a diagnosis.
OTHER POSSIBLE APPLICATIONS IN MEDICINE
We have begun testing the OBS to assess its ability to detect ocular pathologies other than cancer. Preliminary measurements of human eye lenses indicate that the biochemical breakdown products of UV photo-damage, which eventually lead to cataract formation, can be detected in lenses at relatively young ages11. There is a correlation between the fluorescence signal and the age of human lenses. Recently, we have begun a study to determine the utility of the OBS technology in diagnosing corneal infections of the types typically experienced by contact lens wearers. Among gynecological applications, we speculate that diagnosis of endometriosis could be made quick and easy. (Although this is not cancer, cellular architecture differences are the key to diagnosis.) Finally, the diagnosis ofgum disease may yield to OBS technology.
